Dutch biotech company Pepscope, offering endogenous protein kinase activity profiling technologies, has secured €4.3 million funding to further develop and commercialize their lead product QuantaKinome.
QuantaKinome is the first technology to provide direct insights into the activities of hundreds of protein kinases simultaneously inside the cells of diseased tissues. Pepscope offers Quanta- Kinome to the pharmaceutical industry and academic researchers to improve the discovery and development of novel kinase inhibitors and other therapeutic compounds, to find new applications of existing compounds, and in due course to select optimal therapies for individual patients.
Kinase inhibitors represent an essential class of targeted therapies that exert their effects by influencing signalling networks inside cells, governed by protein kinases. Despite impressive scientific progress, little is known about the complex effects of drugs on these networks inside tissues.
Commenting on the funding, Anna Ressa, CEO & co-founder of Pepscope, said: “With this investment, we are fully equipped to expand our business globally and work on novel solutions for drug development with pharmaceutical partners.”